WP
RIGL icon

Woodline Partners’s Rigel Pharmaceuticals RIGL Stock Holding History

Woodline Partners’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.96M Hold
50,000
– – 0.01% 842
2026
Q1 		$1.35M Hold
50,000
– – 0.01% 843
2025
Q4 		$2.14M Buy
+50,000
New +$1.88M 0.01% 761
2022
Q3 		– Sell
-86,131
Closed -$973K – 811
2022
Q2 		$973K Buy
86,131
+3,765
+5% +$75.6K 0.02% 520
2022
Q1 		$2.46M Buy
+82,366
New +$2.23M 0.04% 351

Other funds holding RIGL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Woodline Partners's RIGL Position: Q2 2026 in Review

Woodline Partners held its Rigel Pharmaceuticals (RIGL) position steady in Q2 2026 at 50,000 shares worth $1.96M. The position accounts for 0.01% of the portfolio, ranked #842.

Woodline Partners first reported a position in RIGL in Q1 2022 and has held it in 5 quarters since. The position peaked at $2.46M in Q1 2022. 156 funds tracked by Wall St. Rank hold RIGL as of Q2 2026.

  • Woodline Partners held 50,000 shares of Rigel Pharmaceuticals worth $1.96M as of Q2 2026.
  • Woodline Partners left its Rigel Pharmaceuticals share count unchanged in Q2 2026.
  • Rigel Pharmaceuticals made up 0.01% of Woodline Partners's portfolio in Q2 2026, its #842 holding.
  • Woodline Partners first reported a position in Rigel Pharmaceuticals in Q1 2022 and has held it in 5 quarters since.
  • Woodline Partners's Rigel Pharmaceuticals position peaked at $2.46M in Q1 2022.
  • 156 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q2 2026.

Based on Woodline Partners's 13F filing for Q2 2026, filed 14 Aug 2026.